Dopamine receptor partial agonists and addiction.

European Journal of Pharmacology
Fabricio A Moreira, Jeffrey W Dalley

Abstract

Many drugs abused by humans acutely facilitate, either directly or indirectly, dopamine neurotransmission in the mesolimbic pathway. As a consequence dopamine receptor agonists and antagonists have been widely investigated as putative pharmacological therapies for addiction. This general strategy, however, has had only limited success due in part to poor treatment adherence and efficacy and the significant adverse effects of dopaminergic medications. In this perspective, we discuss the potential therapeutic use of dopamine receptor partial agonists in addiction, developed initially as antipsychotic agents. Recent research indicates that the dopamine D2 receptor partial agonists, such as aripiprazole, also shows useful ancillary efficacy in several animal models of psychostimulant and opioid addiction. Notably, these findings suggest that unlike full dopamine receptor agonists and antagonists these compounds have low abuse liability and are generally well tolerated. Indeed, partial dopamine agonists attenuate the rewarding properties of opioids without interfering with their analgesic effects. Herein we discuss the utility and potential of dopamine receptor partial agonists as treatments for both stimulant and non-stimulant drug...Continue Reading

References

Sep 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A Carlsson
Oct 1, 1994·Trends in Pharmacological Sciences·L Pulvirenti, G F Koob
Feb 5, 1996·European Journal of Pharmacology·G BonoL Pulvirenti
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C OrsiniL Pulvirenti
Apr 17, 2002·Journal of Neural Transmission·C A Tamminga
May 30, 2002·Progress in Neurobiology·Mark J Millan
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Nov 19, 2003·The Journal of Pain : Official Journal of the American Pain Society·Ewan McNicolUNKNOWN Americal Pain Society
Dec 6, 2003·Pharmacological Reviews·Richard R NeubigUNKNOWN International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification
May 21, 2004·Nature Reviews. Neuroscience·Roy A Wise
Jul 28, 2004·Trends in Pharmacological Sciences·Shitij Kapur
Sep 11, 2004·Journal of Psychopharmacology·Tsuyoshi HiroseToshitaka Nabeshima
Apr 21, 2005·European Journal of Pharmacology·Fabrício A Moreira, Francisco S Guimarães
Jun 29, 2005·Journal of Psychopharmacology·R I Ohlsen, L S Pilowsky
Oct 28, 2005·Nature Neuroscience·Eric J Nestler
Oct 28, 2005·Nature Neuroscience·Barry J Everitt, Trevor W Robbins
Dec 2, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sridhar NatesanShitij Kapur
Jun 30, 2006·Biological Psychiatry·Matthew W FeltensteinRonald E See
Mar 1, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sunmee WeeGeorge F Koob
Feb 20, 2008·Psychopharmacology·Margaret Haney, Roger Spealman
May 13, 2008·Trends in Pharmacological Sciences·Philip G Strange
May 16, 2008·Psychopharmacology·Gunnar SørensenDavid P D Woldbye
Apr 9, 2009·Pharmacology, Biochemistry, and Behavior·Su-xia LiLin Lu
Aug 28, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·George F Koob, Nora D Volkow
Sep 5, 2009·Trends in Pharmacological Sciences·Angelo A IzzoRaphael Mechoulam
Oct 23, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Morgane BessonJeffrey W Dalley
Aug 12, 2010·Journal of Psychopharmacology·Caroline BiojoneFabrício A Moreira
Feb 2, 2012·Journal of Pharmacological Sciences·Masahiro ShibasakiSeitaro Ohkuma
Jun 8, 2012·Cold Spring Harbor Perspectives in Medicine·R Christopher PierceLouk J M J Vanderschuren
Nov 20, 2012·Basic & Clinical Pharmacology & Toxicology·Thercia G VianaFabricio A Moreira
Dec 6, 2012·British Journal of Clinical Pharmacology·James Bell
Mar 16, 2013·British Journal of Clinical Pharmacology·Henri-Jean AubinIvan Berlin
Dec 19, 2013·The International Journal of Neuropsychopharmacology·Eduardo A V MarinhoRoberto Frussa-Filho
Apr 24, 2014·JAMA : the Journal of the American Medical Association·Barbara S Connolly, Anthony E Lang
Sep 15, 2014·European Journal of Pharmacology·Ana F Almeida-SantosFabricio A Moreira

❮ Previous
Next ❯

Citations

Sep 1, 2015·Naunyn-Schmiedeberg's Archives of Pharmacology·Luara A BatistaFabrício A Moreira
Dec 17, 2016·Journal of Medicinal Chemistry·Mayako MichinoLei Shi
Nov 10, 2018·Nature Reviews. Drug Discovery·Ichio ShimadaKurt Wüthrich
Jan 21, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·Laila AsthFabrício A Moreira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.